John Murphy, PhD, and Tia DiTommaso, PhD, of Arbor Biotechnologies, discussed ABO-101, the company’s gene therapy for primary hyperoxaluria type 1.
Tia DiTommaso, PhD
Advertisement
Senior Director, Preclinical Pharmacology at Arbor Biotechnologies
Articles by Tia DiTommaso, PhD
The chief scientific officer and senior director of preclinical pharmacology Arbor Biotechnologies discussed ABO-101, the company’s gene therapy for primary hyperoxaluria type 1.
Advertisement
Latest Updated Articles
John Murphy, PhD; and Tia DiTommaso, PhD, on Preclinical Evidence for PH1 Gene TherapyPublished: September 2nd 2025 | Updated:
Preclinical Evidence for PH1 Gene TherapyPublished: September 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
3
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
4
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD
5
